首页> 美国卫生研究院文献>JNCI Journal of the National Cancer Institute >Improving the Biomarker Pipeline to Develop and Evaluate Cancer Screening Tests
【2h】

Improving the Biomarker Pipeline to Develop and Evaluate Cancer Screening Tests

机译:改善生物标志物管线以开发和评估癌症筛查测试

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The biomarker pipeline to develop and evaluate cancer screening tests has three stages: identification of promising biomarkers for the early detection of cancer, initial evaluation of biomarkers for cancer screening, and definitive evaluation of biomarkers for cancer screening. Statistical and biological issues to improve this pipeline are discussed. Although various recommendations, such as identifying cases based on clinical symptoms, keeping biomarker tests simple, and adjusting for postscreening noise, have been made previously, they are not widely known. New recommendations include more frequent specimen collection to help identify promising biomarkers and the use of the paired availability design with interval cases (symptomatic cancers detected in the interval after screening) for initial evaluation of biomarkers for cancer screening.
机译:用于开发和评估癌症筛查测试的生物标志物管线包括三个阶段:确定有前途的生物标志物以早期检测癌症,初步评估生物标志物以进行癌症筛查以及最终评估生物标志物以进行癌症筛查。讨论了改善这一流程的统计和生物学问题。尽管先前已经提出了各种建议,例如根据临床症状确定病例,保持生物标志物测试简单以及针对筛查后的噪音进行调整,但这些建议尚未广为人知。新的建议包括更频繁地收集标本,以帮助鉴定有前途的生物标志物,并将配对的可用性设计与间隔病例(筛查后间隔内发现的症状性癌症)一起用于癌症筛查的生物标志物初步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号